Newcastle disease M1N strain, modification method and recombinant vaccine preparation method
By performing two-point mutation and HN protein replacement of the M protein of the LaSota vaccine strain, the M1N strain of Newcastle Disease was constructed, solving the problem of low immune protection efficiency of existing vaccines in the parent antibody environment, and achieving efficient proliferation and thermal stability , overcomes maternal antibody interference, provides stronger immune protection and efficient vaccine production.
Patent Information
- Application Number
- CN202411115646.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-14
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing Newcastle Disease Virus vaccine has low immune protection efficiency in the presence of maternal antibodies, and insufficient proliferation efficiency and chicken embryo yield, which cannot effectively respond to genotype matching and thermal stability requirements.
By performing R247K and S263R double-point mutation of the M protein of the LaSota vaccine strain and replacing it with the optimized and modified HN protein, a Newcastle Disease M1N strain matching the NDV gene VII was constructed to improve the thermal stability and proliferation efficiency of the virus. Overcome the interference of maternal antibodies and prepare an efficient recombinant vaccine.
The constructed recombinant vaccine has higher proliferation efficiency and improved thermal stability on chicken embryos, which can effectively stimulate antibodies in a high-maternal antibody environment, reduce the cost of vaccine cold chain transportation, and provide stronger immune protection.
Smart Images

Figure CN119020301A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of genetic engineering, and specifically relates to a Newcastle disease M1N strain and a transformation method and a recombinant vaccine preparation method. Background Art
[0002] Newcastle disease virus (NDV) is one of the highly contact and severe animal infectious pathogens that endanger the global poultry industry. The World Organization for Animal Health (WOAH) lists Newcastle disease (ND) as an infectious disease that must be reported. NDV belongs to the Paramyxoviridae family, the mumps virus genus, and the avian mumps virus type I. It is a type of enveloped single-stranded negative-stranded non-segmented RNA virus. Its genome encodes six structural proteins, NP-PMF-HN-L, in sequence. Among them, the HN protein is a membrane surface protein and the most important antigenic protein of NDV. Its genome length is 2002nt, but different NDV strains have different protein lengths due to the different positions of the stop codons of their HN open reading frames (ORFs). At present, at least 9 different lengths of HN proteins have been reported, and the protein molecular weight is between 72 and 75KD. The main biological function of HN protein is to mediate virus adsorption to host cells (HA activity) and to participate in assisting F protein to complete membrane fusion. At the same time, during the budding process of progeny virus, it exerts NA activity to lyse sialic acid receptors on the cell surface, allowing the progeny virus to successfully leave the host cell.
[0003] All NDVs belong to the same serotype, but are highly diverse at the genetic level. Based on the complete sequence of the F gene, NDV is divided into two major systems: Class I and Class II. Class I is a single genotype, and Class II contains at least 18 genotypes (Ⅰ~ⅩⅧ), which can be divided into slow-type, intermediate-type and rapid-type strains according to their different pathogenicity.
[0004] NDV has only one serotype, so different genotypes can provide cross protection, but there are certain differences in the protection effect, and immunization with the same genotype NDV is the best. The currently widely used vaccine strain La Sota belongs to the genotype II in Class II, while the prevalent strains in my country are mainly genotype VII strains. Although there is an artificially attenuated Class II genotype VII vaccine, its proliferation efficiency and chicken embryo yield are significantly lower than the classic vaccine strain LaSota.
[0005] In addition, the presence of maternal antibodies can also interfere with the immune effect of NDV in poultry. It is reported that NDV vaccine can provide complete immune protection in SPF chickens, while in the presence of maternal antibodies, the same dose of NDV-H5 vaccine has only 50% immune protection efficiency. In another study, researchers found that in the presence of NDV maternal antibodies, the immune dose of the vaccine needs to be increased to overcome the interference of maternal antibodies. Therefore, the development of a new vaccine with genotype matching, high proliferation efficiency, and the ability to overcome the interference of maternal antibodies is of great significance for the prevention and control of NDV. Therefore, a Newcastle disease M1N strain, a modification method, and a recombinant vaccine preparation method are needed. Summary of the invention
[0006] The purpose of the present invention is to provide a Newcastle disease M1N strain and a transformation method and a recombinant vaccine preparation method. The present invention is achieved through the following technical solutions:
[0007] The strain described in the present invention was deposited in the General Microbiology Center of the China Culture Collection Administration on January 19, 2024. The address of the depository unit is No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, CGMCC No. 45869. The classification name of the strain is Newcastle disease virus strain.
[0008] Furthermore, the nucleotide sequence of the Newcastle disease M1N strain is shown in SEQ ID No.3.
[0009] A method for transforming a Newcastle disease M1N strain, comprising:
[0010] The M protein of the LaSota vaccine strain was subjected to double point mutations of R247K and S263R;
[0011] The corresponding sequence of the HN protein of the LaSota vaccine strain was replaced with the optimized HN protein, and the NDV-M1N vaccine strain matching the NDV genotype VII was rescued using reverse genetics technology. The nucleotide sequence of the optimized HN protein is shown in SEQ ID No.1, and the amino acid sequence of the HN protein is shown in SEQ ID No.2.
[0012] The Newcastle disease M1N strain is used to promote the thermal stability and proliferation of Newcastle disease virus.
[0013] The application of the Newcastle disease M1N strain in promoting the antibody stimulating ability in animals with high maternal antibodies.
[0014] Compared with the prior art, the present invention adopts the above technical solution, and the biggest feature is:
[0015] (1) The recombinant vaccine strain constructed by the present invention has the same antigenic sites as the current NDV genotype VII epidemic strain, and has a high proliferation efficiency that exceeds that of the classic vaccine strain La Sota, thereby improving the thermal stability of the NDV vaccine strain and helping to reduce the cost of cold chain transportation of vaccines.
[0016] (2) Compared with La Sota, the recombinant vaccine strain constructed by the present invention has a higher proliferation efficiency in chicken embryos, better antigenicity of the inactivated vaccine of the recombinant vaccine strain, and a higher level of antibodies stimulated; and it can also stimulate effective antibody levels in chickens with high levels of maternal antibodies. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 A schematic diagram of the construction of a recombinant virus of a Newcastle disease M1N strain and a transformation method and a recombinant vaccine preparation method of the present invention;
[0018] Figure 2 A titer graph of a Newcastle disease M1N strain, a transformation method, and a recombinant virus for preparing a recombinant vaccine according to the present invention;
[0019] in, Figure 2 A is the HA titer of the virus proliferation in SPF chicken embryos, Figure 2 B is the HA titer of the virus propagated in commercial chicken embryos;
[0020] Figure 3 A growth curve measurement diagram of a recombinant virus drawn from quantitative detection data of a Newcastle disease M1N strain, a transformation method, and a recombinant vaccine preparation method of the present invention;
[0021] in, Figure 3 A is the quantitative detection data of NP gene by qPCR; Figure 3 B is the quantitative detection data using virus TCID50;
[0022] Figure 4 A comparison diagram of the effects of heat treatment on the HA activity of the recombinant virus of a Newcastle disease M1N strain, a transformation method, and a recombinant vaccine preparation method of the present invention;
[0023] in, Figure 4 A is the influence diagram of heat treatment at 37 degrees; Figure 4 B is the influence diagram of heat treatment at 58 degrees;
[0024] Figure 5 A comparison chart of serum antibody HI titer changes of SPF chickens inoculated with LaSota and recombinant virus inactivated vaccines according to a Newcastle disease M1N strain, a transformation method and a recombinant vaccine preparation method of the present invention;
[0025] in, Figure 5 A is La Sota antigen; Figure 5B is genotype VII HN antigen;
[0026] Figure 6 The present invention provides a comparative diagram of serum antibody HI titer changes in commercial chickens after inoculation of La Sota and recombinant virus inactivated vaccines with a Newcastle disease M1N strain, a transformation method and a recombinant vaccine preparation method of the present invention.
[0027] in, Figure 6 A is La Sota antigen; Figure 6 B is genotype VII HN antigen; DETAILED DESCRIPTION
[0028] The technical scheme of the present invention is further described below in conjunction with embodiments and comparative examples, but they should not be construed as limiting the present invention:
[0029] The nucleotide sequence of the Newcastle disease M1N strain is shown in SEQ ID No. 3; the cell strain was deposited in the General Microbiology Center of the China Culture Collection Administration on January 19, 2024, and the address of the depository unit is No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, CGMCC No. 45869, and the classification name of the strain is Newcastle disease virus strain.
[0030] A method for modifying a Newcastle disease M1N strain comprises: using a La Sota vaccine strain as a skeleton, replacing a corresponding sequence of an HN protein of the La Sota vaccine strain with an artificially designed and synthesized gene type VII HN protein antigenic determining region, rescuing an NDV-M1N vaccine strain matching the NDV gene type VII by reverse genetics technology, and optimizing the nucleotide sequence of the modified HN protein as shown in SEQ ID No.1, and the amino acid sequence of the HN protein as shown in SEQ ID No.2.
[0031] Configuration of main reagents
[0032] 1) Non-resistant liquid LB bacterial culture medium:
[0033]
[0034]
[0035] Use 800mL ddH2O to dissolve and dilute the above solid reagents. After complete dissolution, add 200mL ddH2O to make up to 1L and sterilize under high pressure for storage.
[0036] (2) Resistance solid LB bacterial culture medium:
[0037]
[0038] Use 800mL ddH2O to dissolve and dilute the above solid reagents. After complete dissolution, add 200mL ddH2O to make up to 1L. Autoclave and wait until it cools to about 60°. Add Ampicillin or Kana at a final concentration of 100μg / mL. Mix well with the culture medium and slowly pour into a disposable bacterial culture dish on a clean bench. After cooling and solidifying, seal and store at 4°.
[0039] Test methods
[0040] Construction of full-length plasmid
[0041] Homologous recombination primer design
[0042]
[0043]
[0044] Plasmid construction method
[0045] ① Use ApexHF HSDNA polymerase-CL from Apex to amplify the corresponding target fragment. The PCR amplification system is as follows:
[0046] First, take 1 μL of plasmid and dilute it to 10 ng / μL with ultrapure water for use as a template, then prepare the PCR system according to the table below.
[0047]
[0048] ②PCR reaction conditions:
[0049]
[0050]
[0051] ③After the PCR is completed, the PCR product is subjected to agarose gel electrophoresis.
[0052] Prepare 1% agarose gel: weigh 0.6g agarose and place it in a conical flask, add 60mL 1×TAE electrophoresis buffer, heat for three minutes until the agarose is completely dissolved in the electrophoresis buffer, add 1μL green like blue, shake the system and gently introduce it into the agarose gel plate, insert the hole comb according to the sample volume, and wait for it to cool and solidify before use.
[0053] Add 10× loading buffer to the PCR product, mix well, and then load all the PCR products to obtain the maximum DNA recovery. Perform agarose electrophoresis at a constant voltage of 120V. After 30-40 minutes, the gel is taken out and placed in a gel imaging system for photography. Then, the target DNA band of about 1100 bp is cut out under simulated ultraviolet light.
[0054] ④ Connect the target fragment to the vector
[0055] After the PCR amplification product is correctly identified by agarose gel electrophoresis, it is purified by gel recovery, and then the template is digested with DpnⅠ enzyme, and gel recovery and purification are performed again. The fragments are connected using the full-length gold seamless cloning kit. The recommended amount of vector and target fragment is 0.01-0.25 pmols, and the optimal molar ratio is 1:2. The connection system is shown in the following table:
[0056]
[0057]
[0058] Mix gently and react at 50°C for 15 minutes. After the reaction, place the centrifuge tube on ice to cool for a few seconds. The recombinant product is transformed with HST08 competent cells.
[0059] ⑤ Pick at least 6 monoclonal colonies from each Amp-resistant LB plate coated with the transformed recombinant product, add them to 1 mL of LB medium containing Amp resistance and shake them at 30°C for 20 hours. After the bacterial solution becomes turbid, perform PCR identification on the bacterial solution to screen for positive bacteria.
[0060] Bacterial liquid PCR system and reaction conditions:
[0061]
[0062] PCR reaction conditions:
[0063]
[0064]
[0065] After PCR, the PCR products were subjected to agarose gel electrophoresis, and the bacterial solution with positive specific bands was selected. 200 μL of the bacterial solution was sent to Sangon Biotech for sequencing. The bacterial solution with correct sequencing results was retained for expansion culture, and the plasmid was extracted using the QIAGEN midi extraction kit and stored at -20°C.
[0066] Virus rescue
[0067] NDV La Sota was rescued using the NDV T7 RNA polymerase-dependent rescue system. The specific steps are as follows:
[0068] To maximize the rescue efficiency, BSR-T7 / 5 cells were revived two days before rescue and cultured in DMEM medium containing 1 mg / mL G418 without repeated passages. 12 h before transfection, cells were seeded in six-well plates and cultured in DMEM without antibiotics and containing 10% FBS. Cells were used for transfection when the cell density was about 60% to 80%;
[0069] Before transfection, dilute the frozen MVA 500 times with blood-free and antibody-free DMEM for later use. Take out the six-well plate, wash the cells three times with high-pressure sterile PBS, add 600 μL of the vaccinia virus MVA dilution to each well of the six-well plate, and place it in a 37°C, 5% CO2 incubator for adsorption for 30 minutes;
[0070] First, add 100 μL of Opti-MEM to EP tube A, add 10 μL of FuGENE HD to tube A at a ratio of 1:3 for the total number of FuGENE HD transfection reagent and plasmid, mix well and let stand for 5 minutes. After 5 minutes, add the four point mutation M protein LaSota full-length plasmids and auxiliary plasmids to EP tube A at a ratio of pCI-NP: pCI-P: pCI-L: full-length plasmid = 2.0 μg: 1.0 μg: 0.5 μg: 5.0 μg, gently blow and mix, and incubate for 15 minutes to form a transfection complex; a negative control needs to be designed at the same time. During this period, the BSR cells incubated with vaccinia virus MVA were washed three times with autoclaved sterile PBS, and 1 mL of Opti-MEM was added to each well of the six-well plate. After the incubation is completed, the transfection complex is evenly added to each well and cultured normally in a 37°C incubator for 50-60 hours.
[0071] 24 hours after transfection, add 1 μg / mL TPCK trypsin or 200 μL fresh SPF chicken embryo allantoic fluid to each well of the six-well plate, and observe the cell status every 8-12 hours. If the cells show dead floating phenomenon, add 200 μL FBS to each well.
[0072] 60h after transfection, collect the cell supernatant in a sterile EP tube, gently digest the adherent cells with 200μL trypsin in each well of the six-well plate, discard the trypsin digestion solution, and gently blow off the cells with the collected cell supernatant and collect them together in the EP tube. This step requires caution to avoid contamination that affects the rescue efficiency.
[0073] Fresh supernatant was directly taken to inoculate 9-day-old SPF chicken embryos, 200 μL / egg. The inoculated SPF chicken embryos were placed in a 37°C chicken embryo incubator for 96 hours.
[0074] After 96 hours, the chicken embryos were taken out and placed at 4°C overnight. The allantoic fluid was collected the next day, and the hemagglutination titer of the chicken embryos was measured according to the OIE standard to determine whether the rescue was successful. If the rescue was successful, the virus was passaged to the third generation and the allantoic fluid RNA was extracted. After reverse transcription into cDNA, PCR was amplified for the full-length sequence, the point mutation-specific fragment of the M protein and the HN gene fragment were sent for testing and identification.
[0075] Chicken embryo allantoic fluid inoculation
[0076] Fresh SPF-grade chicken embryos should be used for virus rescue. The unhatched chicken embryos should be placed in a chicken embryo incubator at 38°C and a humidity of about 60% for incubation in preparation for 9-day-old inoculation. During the incubation period, the eggs should be turned on time and the position of the embryos should be changed in time so that all parts of the chicken embryos are heated evenly to facilitate embryonic development, prevent the embryos from sticking to the shell, and improve the hatching rate.
[0077] When the chicken embryo is 9 days old, the embryo is illuminated and the position of the embryo's air chamber is clearly marked for subsequent needle insertion and inoculation. The chicken embryo is taken out and placed in a clean bench. The needle insertion position of the chicken embryo's air chamber is first lightly wiped and disinfected with an iodine cotton ball. After 5 minutes, the chicken embryo is repeatedly wiped with a 75% alcohol cotton ball for deiodination.
[0078] (1) Disinfect metal tweezers with 75% alcohol cotton balls and place them on an alcohol lamp to burn for thorough disinfection. After cooling, use the sharper end of the tweezers to quickly tap the top of the chick embryo's air chamber to make a small hole. Use a disposable sealed sterile 1mL needle to inoculate 100-200μL of virus dilution or cell transfection solution per chick embryo.
[0079] (2) Finally, use paraffin to seal the needle hole to prevent contamination. After the chicken embryos were cultured in a 37°C chicken embryo incubator for 96 hours, the chicken embryo allantoic fluid was carefully collected in a clean bench to test the blood coagulation value.
[0080] (3) Extraction and reverse transcription of viral RNA
[0081] (4) Using an RNase-free tip pipette in a clean bench, mix the rescued chicken embryo allantoic fluid and TRIzol extraction reagent in a 1:1 ratio by pipetting and placing them in an RNase-Free EP tube;
[0082] (5) Add 200 μL of chloroform to each EP tube, shake vigorously for 15 seconds, and let stand at room temperature for 2-3 minutes; (6) Centrifuge at 4°C and 12,000×g for 15 minutes. After centrifugation, the liquid phase is divided into three parts: the upper colorless aqueous phase, the middle layer attached to the EP tube wall, and the red chloroform phase. RNA only exists in the upper colorless aqueous phase. (7) Transfer the upper aqueous phase to a new RNase-Free EP tube, add an equal volume of isopropanol, mix back and forth several times, and place at -20°C for 30 minutes to precipitate the RNA. After precipitation, centrifuge at 4°C and 12,000×g for 15 minutes.
[0083] (8) Prepare 75% ethanol using DEPC water. After centrifugation, carefully discard the supernatant and retain the RNA precipitate. Add 1 mL of 75% ethanol to each EP tube and gently pipette. Centrifuge at 4°C and 12,000 × g for 15 min. Repeat twice, empty the tube for 5 min, and use a 10 μL Tip pipette to absorb any remaining liquid.
[0084] (1) After removing and drying excess ethanol in a clean bench, add DEPC water to combine with RNA and perform reverse transcription according to the following system.
[0085]
[0086]
[0087] (2) After mixing DEPC water and primers, mix well and centrifuge briefly, place in a 70°C water bath for 10 min, and then place on ice for 5 min;
[0088] (3) After mixing all the above systems, place them in a 37°C water bath for 2 hours, inactivate them at 75°C for 5 minutes, and store the reverse transcription products at -20°C.
[0089] Virus pathogenicity determination
[0090] According to OIE standards, the embryonic infective dose (EID) of the fifth-generation recombinant virus and its parental virus 50 ), mean lethal time (MDT) of chicken embryos and intracerebral pathogenicity index (ICPI) of one-day-old chicks. Determination of the half infectious dose of chicken embryos: The recombinant virus and the original virus were diluted 10 times in a row, and 10-5 to 10-6 dilutions were taken to inoculate 9-day-old chicken embryos. Five chicken embryos were inoculated at each dilution, and 100 μL was used for each embryo. The chicken embryos that died within 24 hours were discarded, and the activity of each chicken embryo was detected after incubation at 37°C for 4 days. The half infectious dose of chicken embryos was calculated according to the Reed-Muench method.
[0091] Determination of average lethal time of chicken embryos: The recombinant virus and the original virus were diluted 10 times in a row, and the dilutions of 10-6 to 10-9 were inoculated into chicken embryos. Five 9-day-old SPF chicken embryos were inoculated through the allantoic cavity at each dilution, with 100 μL per embryo. The chicken embryos were then cultured in a 37°C incubator, and the chicken embryos that died within 24 hours were discarded. The death time and number of chicken embryos inoculated with each dilution were checked and recorded every 12 hours. After 7 consecutive days of observation, the average time of all deaths when the chicken embryos were inoculated with the highest virus dilution was the MDT of the virus.
[0092] Determination of intracerebral pathogenicity index: The recombinant virus and the original virus were diluted 10 times with sterile water, and 10 one-day-old chickens were inoculated intracerebrally (50 μL / chicken). The chickens were observed once a day for 8 consecutive days, and the chickens were scored according to the scoring criteria, with normal chickens scored as 0, diseased chickens scored as 1, and dead chickens scored as 2. After 8 consecutive days of observation, the ICPI value was calculated according to the OIE standard.
[0093] Preparation method of inactivated vaccine Virus inactivation: Before inactivation, prepare 2% β-propiolactone with ice sterilized water, and mix thoroughly at the ratio of virus solution: 0.5M disodium hydrogen phosphate buffer: 2% β-propiolactone = 38:1:1, ensuring that β-propiolactone and virus particles are evenly mixed and placed on a roller at 4°C overnight. After adjusting the pH value of the solution to 7.3-7.4 with 7% disodium bicarbonate, conduct a safety inspection by blindly passing the inoculated chicken embryos for three generations. The hemagglutination results are all negative, indicating that the virus is completely inactivated.
[0094] Emulsification: The inactivated virus and ISA78 adjuvant are mixed in a ratio of 3:7 and vigorously shaken in a mercury blender until the vaccine drops into water without dispersing, indicating complete emulsification.
[0095] HI determination method
[0096] Venous blood was collected from chickens in each group on days 3, 7, 10, 14, 21, and 28 after immunization for serum separation and detection of NDV-specific antibody levels. The homologous antigen strain DM-JSDHN and the heterologous antigen strain La Sota were used for antibody detection. The specific methods are as follows:
[0097] Add 25μL of PBS to each well of the 96-well microplate, draw 25μL of the serum to be tested and add it to the first well, so that the serum to be tested and the sterilized PBS can be fully mixed, and then draw 25μL of liquid and move it to the second well. Repeat the above method to dilute the serum in multiples. Finally, the serum dilution multiple detected is 1:2 to 1:211. After the entire microplate dilution is completed, add 25μL of four units of antigen to each well, shake and mix evenly, and place at room temperature for 1h to 1.5h. Add 25μL of red blood cell suspension to each well, shake and mix evenly, and place at room temperature for 30min before judging the result. The highest dilution that makes the red blood cells completely agglutinate is the judgment end point.
[0098] Construction of recombinant viruses
[0099] In order to achieve the effect of homotypic immunity, we used the current vaccine strain La Sota as the skeleton and replaced the original HN protein head with the artificially designed and synthesized gene VII type HN protein head. At the same time, according to the laboratory's previous research, the NDV M protein R247K and S263R mutations can improve the virus budding efficiency by affecting the nuclear efficiency of the M protein, thereby improving the virus's replication ability. Therefore, we performed R247K and S263R double point mutations in the M protein of the recombinant virus to improve the proliferation efficiency of the recombinant virus, thereby constructing the recombinant virus NDV-M1N (such as Figure 1 shown).
[0100] Determination of biological characteristics of recombinant viruses
[0101] Determination of the proliferation efficiency of recombinant viruses in chicken embryos
[0102] In order to study whether the modified vaccine strain would affect the replication of the virus in chicken embryos, we collected more than 50 SPF chicken embryos and more than 30 commercial chicken embryo allantoic fluids to measure the hemagglutination (HA) titer. The results showed that (see Figure 2 ), the proliferation efficiency of NDV-M1N was significantly higher than that of LaSota.
[0103] HA, MDT, ICPI, EID of recombinant virus 50 and TCID 50 Determination
[0104] After the first generation of recombinant virus was rescued, the virus was continuously subcultured to the fifth generation, and each virus was diluted to 10 -4 Each recombinant virus was inoculated with at least 10 embryos, and each embryo was inoculated with 100 μL of virus dilution. After 96 hours of inoculation and culture, the allantoic fluid containing the recombinant virus was collected to measure the HA titer, mean embryo mortality time (MDT), intracerebral pathogenicity index (ICPI) of one-day-old chickens, and embryonic infection dose (EID) of 50%. 50 ) and TCID 50 ). The results showed (as shown in Table 1) that the titer of the recombinant virus NDV-M1N was higher than that of La Sota, and there was no significant difference in virulence.
[0105] Table 1 HA, MDT, ICPI, EID of the fifth generation recombinant virus 50 and TCID 50 Determination
[0106]
[0107] Growth curve assay of recombinant virus
[0108] The recombinant virus was inoculated into DF-1 cells at an MOI of 5. The cell supernatants were collected at 6 / 12 / 18 / 24 / 30 / 36 h. RNA was extracted from one part of the cells and reverse transcribed into cDNA for RT-PCR amplification of the La Sota NP gene. The other part was inoculated into BHK21 cells for TCID 50 The results showed that the recombinant strain NDV-M1N was released faster on cells than La Sota (see Figure 3 ).
[0109] Improved thermal stability of recombinant viruses
[0110] The thermal stability of vaccines is of great significance for reducing the cost of cold chain transportation of vaccines. To this end, the present invention measured the HA activity of the recombinant virus after treatment at 37°C and 56°C. The results showed ( Figure 4 and Table 2), the HA activity of the recombinant virus NDV-M1N was not greatly affected when stored at 37°C for 72h, but when heated at 56°C for 10 minutes, the HA activity and infectivity of La Sota were completely lost, while the HA activity of the recombinant virus slowly decreased after heating at 56°C, and the HA activity was completely lost until 30 minutes. These results indicate that the thermal stability of the recombinant virus NDV-M1N is improved compared to the parent strain.
[0111] Table 2 TCID of recombinant viruses after heat treatment at 56°C 50 Detection
[0112]
[0113] Recombinant virus inactivated vaccine induces higher antibodies in SPF chickens
[0114] After inactivating the recombinant virus with β-propiolactone at a final concentration of 0.05%, it was mixed evenly with ISA78 adjuvant at a ratio of 3:7, and SPF chickens were immunized as shown in Table 3. Serum was collected on days 3, 7, 10, 14, 21, and 28 after immunization, and the antibody titer was detected using hemagglutination inhibition (HI). The results showed ( Figure 4 ), one week after SPF chickens were immunized with inactivated vaccines, the antibody level in the body began to rise significantly, reaching a peak three weeks after immunization. It is worth noting that compared with La Sota, the antibody level stimulated by the recombinant virus NDV-M1N was significantly higher one week after immunization, especially the antibody titer against genotype VII JSD0812, and the recombinant virus was 2 to 3 log2 higher than the parent strain. The results show that the recombinant virus has a stronger ability to stimulate antibody production.
[0115] Table 3 SPF chicken test grouping
[0116] Group Immune virus Animal species Number of animals Immunization dose Immunization G1 NDV-M1N SPF Chicken 10 0.2mL Subcutaneous injection G2 LaSota SPF Chicken 10 0.2mL Subcutaneous injection G3 PBS SPF Chicken 10 0.2mL Subcutaneous injection
[0117] Recombinant virus can effectively stimulate antibodies in chickens with high maternal antibodies
[0118] In order to study the antibody stimulating ability of the recombinant virus in commercial chickens with high maternal antibodies, the present invention used the same inactivated vaccine as mentioned above to immunize three-day-old commercial chickens as shown in Table 4, and collected serum to measure HI titers before immunization and 3, 7, 10, 14, 21, and 28 days after immunization. The HI titers of the antibodies against LaSota and genotype VII JSD0812 of commercial chickens before immunization were (7.2±0.75)log2 and (7.3±1.35)log2, respectively. The results showed (as shown in Table 4) Figure 6 ), within 10 days after immunization, the antibody titers stimulated by all inactivated vaccines were at a low level. After 14 days of immunization, the serum antibody levels stimulated by the recombinant virus began to rise significantly, while the serum antibody titers of chickens immunized with the parental strain remained at a low level. These results show that LaSota is seriously interfered by maternal antibodies, while the recombinant virus NDV-M1N can overcome the interference of maternal antibodies and stimulate effective antibodies.
[0119] Table 4 Grouping of commercial chickens in the experiment
[0120] Group Immune virus Types of chicken Number of chickens Immunization dose Immunization G1 NDV-MlN Commercial Chicken 10 02mL Subcutaneous injection G2 LaSota Commercial Chicken 10 0.2mL Subcutaneous injection G3 PBS Commercial Chicken 10 0.2mL Subcutaneous injection
[0121] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical scheme and inventive concept of the present invention within the technical scope disclosed by the present invention, which are all covered by the protection scope of the present invention.
Claims
1. A Newcastle disease M1N strain, characterized in that: The strain was deposited in the General Microbiology Center of China Culture Collection Administration on January 19, 2024. The address of the depository unit is No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, CGMCC No. 45869. The classification name of the strain is Newcastle disease virus strain.
2. A Newcastle disease M1N strain according to claim 1, characterized in that: The nucleotide sequence of the Newcastle disease M1N strain is shown in SEQ ID No.
3.
3. A method for transforming Newcastle disease M1N strain, characterized in that: include: The M protein of the LaSota vaccine strain was subjected to double point mutations of R247K and S263R; The corresponding sequence of the HN protein of the LaSota vaccine strain was replaced with the optimized HN protein, and the NDV-M1N vaccine strain matching the NDV genotype VII was rescued using reverse genetics technology. The nucleotide sequence of the optimized HN protein is shown in SEQ ID No.1, and the amino acid sequence of the HN protein is shown in SEQ ID No.
2.
4. Use of the Newcastle disease M1N strain as claimed in claim 1 in promoting the thermal stability and proliferation of Newcastle disease virus.
5. Use of the Newcastle disease M1N strain as claimed in claim 1 in promoting the antibody stimulating ability in animals with high maternal antibodies.
Citation Information
Patent Citations
Recombinant ndv antigen and uses thereof
CN103260643A
Virus strain capable of being used for preparing VII type newcastle disease vaccine and encoding gene thereof
CN105886477A
Recombinant Newcastle disease virus matrix protein and application thereof
CN113214366A
Newcastle disease virus recombinant attenuated strain and preparation and application of vaccine
CN118222521A
Attenuated recombinant newcastle disease virus and vaccine containing the same
US20100183664A1
Cited By
Newcastle disease vaccine strain with high antibody escape capacity and transformation method thereof
CN119913114A
A Newcastle disease vaccine strain with high antibody escape ability and its modification method
CN119913114B
